Cardiol Therapeutics Inc Class A (CRDL) Stock Forecast & Price Target
Cardiol Therapeutics Inc Class A · NASDAQ
$1.16-0.03 (-2.12%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Cardiol Therapeutics Inc Class A, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $8.00 to $9.00, so the covering firms are broadly aligned. The average target of $8.50 sits 636% above the current $1.16. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Cardiol Therapeutics Inc Class A.
As of Jul, 2 of 2 firms rate CRDL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRDL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.14 – $-0.08 · 3 analysts · -14% YoY
Next period, 3 analysts expect Cardiol Therapeutics Inc Class A to earn $-0.10 a share (range $-0.14 – $-0.08), versus $-0.12 a year earlier. Full-year consensus is $-0.36, growing to $-0.28 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $3.3M next year.
Top analysts covering Cardiol Therapeutics Inc Class A
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRDL.
#1
Vernon Bernardino
HC Wainwright & Co. · Rank #379
Buy
$9.00+679.2% to target
Overall win rate
14%
+ Follow
#2
BF
Brandon Folkes
HC Wainwright & Co.
Buy
$9.00+679.2% to target
Coverage
—
+ Follow
#3
EN
Edward Nash
Canaccord Genuity
Buy
$8.00+592.6% to target
Coverage
—
+ Follow
#4
DL
Douglas Loe
Leede Financial
Buy
$11.00+852.4% to target
Coverage
—
+ Follow
CRDL stock forecast FAQ
What is CRDL's average 12-month price target?+
The 2 analysts with a live target average $8.50 for Cardiol Therapeutics Inc Class A over the next 12 months, ranging from a $9.00 high to a $8.00 low.
Is CRDL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRDL?+
The Street-high target is $9.00 (HC Wainwright & Co.), and the Street-low is $8.00 (Canaccord Genuity). The average of all 2 active targets is $8.50.
How many Wall Street analysts cover CRDL?+
2 analysts have an active rating on Cardiol Therapeutics Inc Class A, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRDL?+
Among analysts who currently cover CRDL, Vernon Bernardino of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #379). Their current call is Buy with a $9.00 target.
What is Cardiol Therapeutics Inc Class A's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.14 – $-0.08) across 3 analysts. Full-year EPS is projected at $-0.36, rising to $-0.28 the following year.
How much revenue is Cardiol Therapeutics Inc Class A expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $3.3M next year.
Have analysts been upgrading or downgrading CRDL lately?+
As of Jul, 2 of 2 firms rate CRDL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRDL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
